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1. Introduction. Antibodies versus aptamers   15 
 16 
Biomarkers always have been in the focus of diagnostics and therapeutics, and their 17 
exploitation in clinical trials and medical practice is steadily increasing. Although previous 18 
research activities focused on nucleic acid biomarkers, which led to the development and wide 19 
application of platforms for high-throughput analysis of DNA variants and mRNA expression 20 
profiles, it has been recognized that analysis of protein biomarkers provides larger amount of 21 
relevant information. Progress of proteomics technologies has brought about the explosion of 22 
our knowledge in the field of disease-related protein patterns, and thousands of proteins have 23 
been documented as biomarker candidates [1]. Thus, importance of selective detection and 24 
targeting of individual proteins can hardly be overestimated. Presently, the antibody-based 25 
assays are the most sensitive, specific and selective methodologies for detection and 26 
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characterization of proteins. Consequently, public domain initiatives have been launched to 27 
deposit antibodies against all human proteins in databases with free accessibility (e.g. HUPO 28 
Antibody Initiative) [2]. 29 
Pivotal role of antibodies is not restricted to selective recognition of proteins since their 30 
application is also inevitable in routine diagnostics of small molecules such as antibiotics, 31 
hormones, and food toxins [3].  To meet the receptor demand of therapeutics and diagnostics, 32 
a vast number of antibodies have been produced and various improvements have been made to 33 
their generation. However, application of antibodies is inherently limited by their susceptibility 34 
to environmental conditions, immunogenicity, and in vivo production. Therefore, there is a 35 
continuous quest for appropriate alternatives of antibodies. 36 
It has been long known that single stranded RNAs (ssRNA) form elaborate 3D structures 37 
in ribosomes. Recent discovery of riboswitches has also revealed that several mRNA molecules 38 
could selectively recognize and bind to their matching metabolites, functioning as ancient 39 
bioprobes, predecessors of protein receptors [4]. In a similar manner, the short, single stranded, 40 
in vitro selected DNA or RNA molecules, the so called aptamers also assume specific secondary 41 
structures and oriented conformations, which allows them to selectively bind their target 42 
molecules (Figure 1). The significance of aptamers resides in the possibility of directed 43 
generation of these oligonucleotides for selective binding of theoretically any targeted 44 
compound. The methodology of in vitro selection of oligonucleotides was published almost 45 
simultaneously by two independent research groups in 1990. The term aptamer has been coined 46 
in an article by Ellington and Szostak in Nature [5], while that of “SELEX” (Systematic 47 
Evolution of Ligands by EXponential enrichment) first appeared in a paper in Science authored 48 
by Tuerk and Gold [6]. 49 
Figure 1. 50 
 51 
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While the best dissociation constants of published aptamer–target complexes seem to 52 
be similar to those of antibodyantigens, aptamers are superior to antibodies in several aspects 53 
[9]. These advantages of aptamers can be attributed to their chemical properties and in vitro 54 
selection, and chemical synthesis. Oligonucleotides are conveniently prepared with high 55 
reproducibility and purity; therefore, no batch-to-batch variation is expected in aptamer 56 
production. Moreover, they withstand long-term storage at ambient temperature while 57 
preserving their functionality, which can be tailored on demand during chemical synthesis, e.g., 58 
to aid their immobilization, to impart signaling properties, and/or to increase their resistance to 59 
enzymatic degradation.  Finally, the low immunogenicity and small size of aptamers are 60 
appealing advantages with respect of their therapeutic and diagnostic application. Although all 61 
these properties contribute to the growing popularity of aptamers, their in vitro selection could 62 
probably be highlighted as their most important strength. 63 
The obvious consequence of the living organism-free selection method of aptamers is 64 
that it can be applied where antibody raising would fail, i. e., aptamers can be selected for toxins 65 
as well as for molecules that do not elicit adequate immune response, which outlines the 66 
universal character of the aptamer selection concept [10]. Antibodies are generated in cells and 67 
prone to lose their activity under non-physiological conditions that restricts their diagnostic 68 
utility. On the contrary, application of aptamers is not limited to physiological circumstances 69 
since their selection conditions can be adjusted so as to be equivalent with those of the proposed 70 
in vitro diagnostic exploitation. Additionally, the kinetic parameters such as the on- and off-71 
rates of aptamers could also be finely tuned according to the requirements of the detection 72 
method. A further merit of aptamers is their extreme selectivity that enables them to 73 
discriminate molecules with slight structural differences or even the enantiomers of chiral target 74 
molecules, such as amino acids and drugs [11-13].  75 
 76 
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 77 
2. Aptamer selection 78 
2.1 Basic principles 79 
Like most of the groundbreaking ideas, the theory of SELEX is very simple, relying on 80 
Darwinian evolution at a molecular level. Basically, a vast number (1014-1016) of DNA or RNA 81 
oligonucleotides with different sequences are subjected to selection for binding to the target 82 
molecules. The classical SELEX methodology involves the immobilization of the target 83 
compound on a solid support, which is then brought in contact with the pool of oligonucleotides. 84 
While non-binding oligonucleotides are discarded by washing steps, the bound sequences 85 
exhibiting affinity for the target are amplified by PCR. The multiplied, double stranded DNA 86 
is either converted into ssDNA or used as template for in vitro transcription and the enriched 87 
oligonucleotide library is reintroduced in the follow-up selection cycle. Generally, after 8–15 88 
cycles, the oligonucleotide pool is populated by the best binding aptamer candidates, which are 89 
finally separated and identified by sequencing. The first cycle is decisive for the success of the 90 
whole selection process because hypothetically the oligonucleotide of any possible sequence is 91 
represented only as a single copy in the starting degenerate library. Accordingly, for the initial 92 
round(s) of selection, longer incubation times and less stringent conditions are applied and these 93 
parameters are gradually changed during the subsequent cycles to increase the “selection 94 
pressure”.  95 
The first studies on aptamers involved mostly RNAs, motivated mainly by the 96 
assumption that RNA can form more diverse 3D structures than DNA, which is believed to be 97 
beneficial in terms of establishing a higher affinity to the target. However, the RNA SELEX  is 98 
more complex than the DNA SELEX [14] owing to the fact that additional in vitro transcription 99 
steps are needed before and after each PCR amplification. Additionally, the RNA molecules 100 
5 
 
are prone to enzymatic degradation, which is a major problem to be addressed in most 101 
applications. The authors of this review are not aware of any systematic study indicating a 102 
higher affinity of either type of aptamers. The fact that both RNA and DNA aptamers are 103 
frequently reported to form complexes of submicromolar or even subnanomolar dissociation 104 
constants with their ligands further challenges the assumption of a marked difference between 105 
their affinities. Beside the natural nucleic acids, RNA and DNA libraries containing various 106 
modified nucleotides were also used for generating aptamers. Although the primary motivation 107 
of these efforts was to increase the nuclease resistance of oligonucleotides, several 108 
modifications also conferred aptamers with higher affinity [15]. Recent innovations have added 109 
functional groups that mimic amino acid side-chains to expand the chemical diversity of 110 
aptamers [16, 17]. These latest developments have eliminated one of the drawbacks of 111 
conventional aptamers, namely the lack of hydrophobic moieties. This resulted in drastically 112 
increased success rate of selection and yielded aptamers with subpicomolar affinity. Of note, 113 
both publications have reported application of modified deoxynucleotides prognosticating the 114 
dominance of DNA aptamers in the future.  115 
Figure 2. 116 
 117 
Implementation of aptamer production is much more complex than its simple, theoretical 118 
scheme (Figure 2) would suggest, and the success of the procedure mainly relies on seemingly 119 
minor experimental details of the selection. Consequently, following the introduction of 120 
SELEX, numerous alternative approaches have been explored [18] with the general intention 121 
of increasing the success rate, but also ensuring high speed [19, 20], low handled volumes [21], 122 
minimal contamination and automation [22]. 123 
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The conventional SELEX procedure needs high purity targets to ensure the selectivity 124 
of isolated aptamers. In the case of proteins, this condition is generally fulfilled by using 125 
recombinant proteins with various fusion tags (e.g. polyhistidine and glutathione S-transferase 126 
(GST)). The fusion tags do not only simplify the purification protocol from the protein 127 
overexpressing cell culture or in vitro translation system, but they also enable oriented 128 
immobilization of the targets during the SELEX process; thus, the desired epitope of the protein 129 
could be readily exposed for aptamer generation. 130 
Even if absolute purity of the target protein is assumed, the selection is complicated by 131 
the contingent binding of oligonucleotides to the solid support and the cross-linker used for 132 
immobilization. Therefore, the so called counter selection by which sequences that show cross-133 
reactivity to the matrix components are discarded is of utmost importance in the selection of 134 
highly selective aptamers. The counter selection is a major asset also in developing aptamers 135 
for well specified analytical or therapeutical tasks by eliminating cross reactive aptamers to all 136 
known critical interferents of the sample. Thus, with proper background information on the 137 
support and sample matrix to be involved a more rational selection is possible. Various 138 
development have been made that enable production of aptamers with the desired high 139 
selectivity; however, the opportunities offered by these striking advantages of aptamer-based 140 
assays seems to be less appreciated, as the analytical reports in general do not employ custom-141 
selected original aptamer sequences.  142 
 143 
2.2 Increasing the selectivity  144 
One of the first classical aptamer publications has already demonstrated that the basic 145 
selection method could provide aptamers, which could discriminate among organic dyes with 146 
very similar chemical structures [4]. Since then, panel of modifications have been made to the 147 
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original protocol to increase further the selectivity of generated aptamers. The first 148 
improvement has been described in the publication that presented the selection of DNA 149 
aptamers for the first time [11]. The authors followed their previous protocol used for the 150 
isolation of organic dye selective RNA aptamers, but when the pools that had been selected for 151 
three cycles were applied to non-cognate dye columns, the ssDNA pools bound to every tested 152 
dye, i.e., no selectivity was observed. Apparently, the oligonucleotides were nonspecifically 153 
retained, either because of binding to the agarose matrix or universal dye binding. To remove 154 
nonspecifically binding sequences, negative selection has been introduced, that is the selected 155 
ssDNA pools of third cycle were flown over the non-cognate dye modified columns prior to 156 
next positive selection cycle, which resulted in the removal of the sequences showing cross-157 
selectivity from the selection library. This simple negative selection cycle significantly 158 
increased enrichment of selectively binding oligomers, and has been routinely applied during 159 
aptamer selection since its introduction.  160 
Soundness of this rationale was further validated by production of an RNA aptamer that 161 
binds theophylline with 10,000-fold greater affinity than caffeine, which differs from the target 162 
molecule only by an extra methyl group [8]. The aptamers were isolated by addition of the RNA 163 
pool to theophylline coupled Sepharose column and the stringency of selection was increased 164 
by removing of non-specific binders by washing the column with caffeine before collection of 165 
theophylline selective oligonucleotides. This modified version of negative selection was 166 
designated counter SELEX. Another outstanding example of discriminating capacity of 167 
aptamers was also demonstrated by using negative selection combined with harsh washing 168 
conditions to isolate arginine specific oligonucleotides [9]. The protocol involved a counter 169 
selection with citrulline, but to increase the stringency of competition between free citrulline 170 
and immobilized arginine, the column bound RNA was heat denatured and renatured in the 171 
presence of citrulline before elution with arginine. This rigorous selection scheme led to a tight 172 
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binding RNA aptamer, which discriminates 12,000-fold between the D- and L-enantiomers of 173 
arginine. It should be noted that confusingly, the negative and counter selections have been 174 
widely used as synonymous expressions in the aptamer related publications.   175 
The success of negative and counter selection hinted that beside highly purified proteins, 176 
complex heterogeneous targets are also suitable for generation of specific aptamers. An 177 
important practical application of this theoretical possibility, the so called Cell-SELEX method 178 
isolates cell type specific aptamers by following the above described rationale. It combines 179 
positive and negative selection steps during the selection procedure but uses whole cells instead 180 
of immobilized molecules as targets of aptamers. The most remarkable advantage of this 181 
approach is that cell-specific aptamers can be obtained without any knowledge as to the cell 182 
surface molecules of the target cell. Due to the attractive features of this approach, many 183 
variations of Cell-SELEX have been developed and a wide array of cells has been used as 184 
targets of selection [23]. 185 
 The SELEX most often involves utilization of recombinant proteins, and this could lead 186 
to limited applicability of produced aptamers. Majority of eukaryotic proteins are post-187 
translationally modified and many of them are membrane integrated thus the proteins in their 188 
native conditions are often differently structured from the recombinant variants. Due to the 189 
discriminating capacity of aptamers, using the standard, one ligand SELEX, even a slight 190 
difference of native and recombinant proteins may preclude identification of aptamers, which 191 
maintain their functionality with their physiological targets. This shortcoming of SELEX has 192 
been illustrated with isolation of E-selectin specific thioaptamers [24]. Amongst the 14 193 
aptamers selected by using recombinant protein only one bound to endothelial cells expressing 194 
E-selectin, even though the applied, human recombinant protein had been obtained from 195 
mammalian system. This observation highlights that integration of biologically relevant 196 
conditions into the screening process increases the success rate of identification of aptamers 197 
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with pertinent biological activity. In the last decade, the Cell-SELEX has become a routinely 198 
applied method; therefore, alternation of recombinant proteins and target protein expressing 199 
cells during the steps of selection procedure can be expected to become a more widely applied 200 
aptamer producing approach. 201 
Considering the procedure of translation of lead molecules into therapeutic agents, the 202 
achievable, extremely high-selectivity of aptamers could be also a disadvantage, since the 203 
aptamers isolated for human proteins might possess low affinity for the homologous proteins 204 
of animal models and thus reduced in vivo efficacy. To ensure both the required selectivity and 205 
species cross-reactivity of aptamers intended for therapeutic applications, the toggle SELEX 206 
method was put forward [25]. Using this protocol, nuclease resistant RNA ligands that bind 207 
both human and porcine thrombin with similar affinity have been produced by changing, 208 
“toggling” the human and porcine protein during alternating rounds of selection. The selected 209 
aptamer also has been shown to increase thrombin time in both human and porcine serum 210 
clotting assays. 211 
 212 
2.3 Selection without target immobilization  213 
 214 
 Improvements of the solid supports to minimize oligonucleotide absorption represent an 215 
important aspect in the development of SELEX variants. In any case, additional stringent 216 
counter-selection steps are needed to screen out those oligonucleotides that bind to the support. 217 
Immobilization of the target is also critical in terms of having exposed the desired epitope for 218 
aptamer generation. Therefore, from the plethora of alternative selection methodologies, the 219 
homogeneous approaches need to be highlighted owing to their advantage of not requiring 220 
target immobilization and, consequently, a solid support. These techniques are dominated by 221 
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electrophoretic methods, most notably by capillary electrophoresis [26] and free-flow 222 
electrophoresis [27].  223 
Motivated by the higher efficiency partitioning of kinetic capillary electrophoresis 224 
(KCE) over traditional separation methods by at least two orders [28], capillary electrophoresis-225 
SELEX (CE-SELEX) have been introduced to produce protein selective aptamers [23]. In CE-226 
SELEX the aptamer-target interaction is performed in solution and the high resolving power of 227 
CE is used to separate unbound and target-bound oligonucleotides, the latter being collected 228 
and subjected to PCR amplification before being reinjected. Due to the high separation 229 
efficiency and rate of enrichment, high affinity aptamers are obtained in only 2–4 rounds of 230 
selection [29]. It has been documented that the selection could be distorted by intrinsic 231 
differences in the amplification efficiency of nucleic acid templates; hence, the most abundant 232 
oligonucleotides of SELEX do not necessarily represent the highest affinity aptamers [30]. 233 
Consequently, the reduced number of selection cycles of CE-SELEX not only shortens the time 234 
of aptamer production but also lessens the deleterious effect of extended number of PCRs of 235 
conventional SELEX. In order to further accelerate the selection procedure and to exclude the 236 
DNA amplification bias, repetitive steps of PCR have been completely omitted from the 237 
iterative cycles of selection [31]. This, so called non-SELEX protocol involves less than four 238 
repetitive steps of partitioning by KCE without any amplification between them and provides 239 
protein selective aptamers in less than a week.  240 
To alleviate the PCR bias issue of aptamer selection procedure, a target immobilizing 241 
approach without iterative amplification cycles also has been developed [32]. MonoLex method 242 
relies on application of affinity capillary column coated with the selection target and physical 243 
segmentation of the column into slices following the chromatography of oligonucleotide 244 
library. The different column fragment bound aptamer candidates are separately amplified with 245 
a single PCR and their binding specificity is assessed by dot blot assay.         246 
11 
 
 Although CE-SELEX and non-SELEX have been proved to be fast and effective ways 247 
of isolation of protein selective aptamers, application of these methods also have their own 248 
limitations. Since negative selection is not involved in KCE-based aptamer production, great 249 
purity of target protein is a basic requirement of successful identification of aptamers that are 250 
selective for the protein of interest. Thus, protein sample has to be thoroughly analyzed prior to 251 
its application. The CE-SELEX and non-SELEX protocols can be accomplished in a week; 252 
however, the optimal conditions of partitioning have to be determined individually for each 253 
protein, which could be a challenging task. Furthermore, thermal band broadening of CE due 254 
to Joule heating restricts the applicable ion concentration of partitioning buffers [33]; hence, 255 
the selection conditions might not be adjustable to the circumstances of prospective usage of 256 
aptamers [34]. Finally, one of the benefits of CE-SELEX, i.e., the small analyte requirement is 257 
accompanied with an inherent shortcoming of the approach. The typical sample injection 258 
volume in the range of nanolitres limits the sequence space that can be screened for target 259 
binding. This is contrary to the optimal selection conditions whereas oligonucleotides are added 260 
in large excess over the target molecule so that the probability of the presence of high-affinity 261 
aptamers is increased, and competition for target proteins facilitates isolation of the best binders 262 
from the pool.  263 
Some of the above mentioned disadvantages of CE-SELEX such as sample volume 264 
limitation and selection buffer restrictions may be overcome by using the free-flow 265 
electrophoresis (FFE) technique in which the electrophoretic separation is performed on a 266 
continuous flow of analyte in a planar flow channel. In contrast to CE where the electric field 267 
is applied in the direction of the fluid movement, in FFE, the electric field is applied 268 
perpendicularly to the pressure-driven flow to deflect the analytes laterally according to their 269 
mobility [35]. Aptamers with low nM dissociation constants for protein targets were detected 270 
following a single round of selection with micro FFE [24]. The electrophoresis techniques have 271 
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driven an obvious progress in terms of reducing the selection time; however, apparently there 272 
is no significant improvement in lowering the dissociation constants of the selected aptamers 273 
as compared with conventional SELEX techniques. For instance, dissociation constants of the 274 
aptamers selected for IgE using the conventional SELEX method were as low as 10 nM [36], 275 
somewhat lower than those of aptamers obtained by CE-SELEX  (~ 40 nM [23]) and by micro 276 
FFE (~ 20 nM) [24]. 277 
 278 
2.4 Miniaturization of selection 279 
 In most of the traditional SELEX procedures, non-selective oligonucleotides are 280 
removed from target molecules either via membrane filtration or column chromatography, or 281 
binding of the target protein to the wells of microtiter plates [15]. Due to the low partitioning 282 
efficiency of these separation methods and the binding of oligonucleotides onto the matrix of 283 
stationary phases, isolation of high-affinity, selective aptamers requires typically 8-15 284 
cumbersome selection cycles. A significant improvement has been made to the conventional 285 
selection technology with introduction of paramagnetic beads for target protein immobilization 286 
[22]. Paramagnetic beads offer advantages over column chromatography in their ease of use 287 
even in the microliter range. Hence, very small amounts of target protein coated beads can be 288 
rapidly partitioned, stringently washed, and the protein bound oligonucleotides can be 289 
subsequently eluted. These benefits of paramagnetic beads have made the manual aptamer 290 
selection faster, more straightforward, and provided DNA and RNA aptamers with high affinity 291 
[37, 38]. Significantly, an automated aptamer selection process has also been established by 292 
using paramagnetic beads [22]. The enhanced, fully integrated robotic system accommodates 293 
all steps of the aptamer production including isolation and amplification of selective RNAs. 294 
The reported workstation can carry out eight selections simultaneously and can complete 12 295 
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rounds of selection in two days [39]. The same research group improved the protocol even 296 
further by completing the system with in vitro transcription and translation of target proteins 297 
[40]. In vitro translation is an effective way of high-throughput production of proteins thus 298 
could serve as a supply of target proteins for aptamer selection [41]. Although these results 299 
could make one envision a fully automated pipeline of aptamer production from coding gene to 300 
protein-selective aptamer, the practical, high-throughput application of the combined system 301 
has not been published, yet. 302 
 A mathematical model describing the optimal conditions for SELEX has pointed out 303 
that strong competitive binding of oligonucleotides can yield the highest affinity aptamers [42]. 304 
To achieve the theoretically ideal ssDNA ratio, single microbead SELEX has been developed 305 
and applied successfully for isolation of botulin neurotoxin selective aptamers. However, 306 
manipulation of microscopic amount of beads demands delicate handling, thus it is not suitable 307 
for routine application [43]. The advanced microﬂuidics provide miniaturized sorting 308 
technologies for manipulation of individual particles or cells with continuous operation [44]. 309 
Realizing the benefit of these systems, a chip-based magnetic bead-assisted SELEX with 310 
microfluidics technology, so called magnetic SELEX (M-SELEX) has been invented [45]. 311 
Partitioning efficiency (PE) is a generally accepted indicator of the success of separation. Lou 312 
et al. have demonstrated that the PE of their continuous-flow magnetic activated chip-based 313 
separation (CMACS) device is ca. 106, thus it significantly exceeds the efficiency of 314 
conventional separation methods, and is comparable to that of CE. They combined the 315 
outstanding PE of CMACS device with usage of carboxylic acid activated paramagnetic beads 316 
for target protein immobilization to reduce the nonspecific binding of negatively charged 317 
oligonucleotides onto the beads. The effective separation and low background binding of 318 
oligonucleotide library enabled isolation of Botulinum neurotoxin specific aptamer with low-319 
nanomolar dissociation constant after a single round of selection. However, the use of the 320 
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CMACS needed scrupulous tuning of the device with microscopy to achieve the high PE and 321 
recovery of bead-bound oligonucleotides. To address this shortcoming, the research group 322 
converted the CMACS device into micromagnetic separation (MMS) chip, which is more 323 
robust and does not require a microscope for practical application [46].  Using the MMS chip, 324 
they optimized their previous CMACS-based protocol by determining the ideal buffer flowing 325 
rate, elevating the temperature of selection, and introducing a counter selection step. 326 
 Beside the excellent PE, a further benefit of MMS chip is its capacity to concentrate a 327 
small number of beads suspended in a large volume into a miniature chamber. This feature 328 
facilitates the implementation of the so called sample volume dilution challenge technique 329 
wherein the target-aptamer complexes are equilibrated in increasing volume of buffer during 330 
the consecutive selection cycles to favor enrichment of aptamers with slow off rate. Soh et al., 331 
exploiting the concentrating capability of the MMS chip, have developed an aptamer selection 332 
protocol that combines the volume dilution challenge with high-stringency, continuous washing 333 
inside the chamber of the device. These improvements translated to isolation of aptamers with 334 
less selection cycles. Previously, streptavidin selective aptamers were generated by 335 
conventional magnetic bead-based SELEX with 13 selection cycles, while the MMS chip-336 
based, enhanced protocol provided aptamers for the same target protein with even lower 337 
equilibrium dissociation constants (KD) through 3 iterative steps [47]. 338 
Emerging of M-SELEX approach initiated mathematical remodeling of aptamer 339 
selection procedure and the obtained numerical data highlighted a further advantage of MMS 340 
chip-based method [48]. The authors compared the conventional filter-based SELEX and M-341 
SELEX and their calculations have drawn the attention again to the importance of the non-342 
specific, background binding of oligonucleotides onto the matrix of the stationary phase of the 343 
process. According to the proposed model, the fraction of high affinity aptamers reaches 100 344 
% at the 8th selection cycle with the low background binding M-SELEX, while the application 345 
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of filter for separation yields merely 12 % of high quality aptamers at the same round of 346 
selection. The reduced number of iterative steps apparently implies faster aptamer producing 347 
procedure, but more importantly, it also drastically decreases the enrichment of non-target 348 
selective oligonucleotides resulting from intrinsic differences in the amplification efficiency of 349 
nucleic acid templates. 350 
Although it has been both theoretically and experimentally demonstrated that keeping 351 
the background binding at minimum is a prerequisite of the productive aptamer selection, 352 
density-dependent cooperative (DDC) binding also has to be taken into consideration to evade 353 
the isolation of aptamers with low affinity. DDC binding occurs when the ligand tethers 354 
concurrently to more adjacently immobilized targets in a cooperative mode that could increase 355 
the binding affinity by two orders of magnitude [49]. This phenomenon could deteriorate the 356 
aptamer selection by populating the enriched oligonucleotide library with concurrently binding 357 
aptamers. Considering the comparatively modest number of beads used in M-SELEX, DDC 358 
binding is a particularly important issue with the microfluidic aptamer selection devices. 359 
Therefore, the ratio of magnetic beads and immobilized protein has to be determined according 360 
to the compromise between background and DDC binding. 361 
Table 1. summarizes the characteristics of the best aptamers obtained by the discussed 362 
methods. Closer examination of the data reveals that high-affinity aptamers can be selected with 363 
the traditional SELEX approaches as well, but these procedures demand more selection cycle 364 
thus cannot meet the requirement of an ideal, high-throughput receptor generating system.   365 
 366 
Table 1 367 
 368 
3. Characterization of aptamer candidates 369 
 370 
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Although the success of aptamer production is mainly dictated by the careful planning, 371 
meticulous implementation and following of progression of selection [50], there is another 372 
remarkable aspect of SELEX receiving little attention from the end users of aptamers. Since 373 
most papers feature only a single aptamer, there is little awareness that the selection process 374 
generally results in a large number of sequences. Ideally, all selected oligonucleotides need to 375 
be evaluated individually in terms of their target binding properties to designate the most 376 
auspicious aptamer candidates. Actually, this characterization is one of the most costly and 377 
time-consuming tasks of the aptamer production. The sheer number of methods that have been 378 
used to determine the dissociation constant of aptamer-target molecule complexes speaks both 379 
the importance and difficulty of these measurements. The developed methods range from the 380 
low-cost, simple approaches such as dialysis and filter binding assays to surface plasmon 381 
resonance (SPR) and amplified luminescent proximity homogenous assay (ALPHA) requiring 382 
dedicated instrumentation[27, 51]. As Figure 3 shows, the applied methodologies have different 383 
sensitivities and requirements in terms of estimated analysis time and sample volume. The 384 
measurements are further complicated since post-selection labeling or immobilization of 385 
aptamers may significantly affect their binding distorting the KD of native aptamer. 386 
Additionally, the KD values obtained from different methods could be noticeably divergent [52] 387 
[53].  Considering all of these factors, KD values should be determined with applying a method 388 
that most closely simulates the circumstances in which the aptamer is intended to be used. 389 
Noteworthy messages of these hindrances are that affinity of aptamers is suggested to be 390 
measured by two different approaches and even the most carefully determined KD values have 391 
to be handled cautiously. Altogether, the practical value of aptamers cannot be revealed without 392 
their thorough evaluation in the proposed application.  393 
 394 
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Figure 3. 395 
 396 
4. Outlook 397 
 398 
Aptamers have been around for almost a quarter-century; however, their versatile applicability 399 
was acknowledged only a decade ago. Since then, the aptamer related publications and the 400 
number of selective aptamers has been exponentially increasing, and the aptamers have 401 
appeared on the market, too. Although the theory of aptamer production has not been changed 402 
since its first description, various, crucial modifications have been made to the original SELEX 403 
procedure to enhance the effectiveness of selection. Due to these improvements, the recent 404 
aptamer producing methods require less time and protein, while allow high-throughput isolation 405 
of selective aptamers with high affinity [20, 54]. 406 
It is important to notice that, despite the evident bioanalytical potential of aptamers, their 407 
analytical applications started to appear with a considerable lag. The reason seems to be related 408 
to the lack of an experimental biological background required for aptamer selection in analytical 409 
laboratories. Therefore, the overwhelming majority of the analytically aimed studies were 410 
performed on a relatively limited number of well-characterized model aptamers, such as human 411 
thrombin in ideal samples. The biosensor development was long dominated by glucose 412 
biosensors taking advantage of the highly stable and cheap glucose oxidase enzyme to test and 413 
demonstrate different detection methodologies and materials. Thrombin has become the 414 
dominant target (analyte) in aptamer-based sensing essentially for similar reasons. More than 415 
900 papers have been published on thrombin aptamers to date, which, given the versatility and 416 
almost universal use of aptamers for any target, is hard to be justified by the importance of 417 
thrombin–aptamer recognition alone. Although a limited number of aptamers have been used 418 
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for analytical studies, we have witnessed a tremendous development in the aptamer-based 419 
analytical methodologies in the last decade. Most of the routine immunoanalytical 420 
methodologies were seamlessly adapted to detect aptamer–ligand interactions [55]. Thus, 421 
utilization of aptamers in label-free techniques such as SPR [56], SPR imaging [57], quartz 422 
crystal microbalance [58, 59], microelectromechanical sensors [60], nano field effect transistors 423 
(nanoFETs) [61], and electrochemical impedance spectroscopy [62],  as well as in various 424 
amplification schemes based on enzymes [63], luminescence-generating labels, and 425 
nanoparticles [64, 65] have been demonstrated. Moreover, the range of bioassay methodologies 426 
was further extended by exploiting the inherent properties of nucleic acid aptamers in molecular 427 
beacons [66-68], ligation assays [69], electrophoresis [70], microarrays [71], and direct 428 
reporting through the use of catalytic oligonucleotides (ribozymes and deoxyribozymes) [72]. 429 
Considering that the aptamer production pipeline has become an ideal system for 430 
fulfillment the persistent demand of biomarker selective receptors, and their widespread 431 
analytical application has also been demonstrated, aptamers are expected to be used for 432 
detection of an expanding number of biomarkers and gain ground in routine diagnostics.  433 
 434 
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Table 1. Representative aptamers of various selection procedures.  637 
 
Selection 
method 
Target 
Selection 
rounds 
KD 
Characterization 
method  
Ref. 
Im
m
o
b
il
iz
ed
 t
a
rg
et
 
Conventional SELEX 
Cibacron Blue 3GA 7 100 µM isocratic elution 5 
T4 DNA polymerase 4 5 nM filter binding assay 6 
SELEX with modified 
nucleic acid 
Keratinocyte growth 
factor 
8 0.3-3 pM filter binding assay 15 
Camptothecin 
derivative 
9 86 nM 
surface plasmon 
resonance (SPR) 
17 
Cell-SELEX with 
modified nucleic acid 
E-selectin 10 47 nM 
electrophoretic 
mobility shift assay 
24 
negative Thrombin 5 25-200 nM filter binding assay 14 
Counter 
Theophylline 8 100 nM equilibrium filtration  11 
L-arginine 20 330 nM equilibrium dialysis  12 
Toggle 
Human thrombin 
13 
2.8 ± 0.7 nM 
filter binding assay 25 
Porcin thrombin 83 ± 3 pM 
Monolex Vaccinia virus 1 not available 
fluorescence 
correlation 
spectroscopy 32 
SPR 
SELEX with magnetic 
separation 
Thyroid transcription 
factor 1  
15 3.36 nM SPR 38 
Automated SELEX 
Lysosome 12 31 nM filter binding assay 39 
U1A protein 18 4.5 nM filter binding assay 40 
FluMag-SELEX 
Ibuprofen 10 1.5–5.2 µM equilibrium filtration  13 
Streptavidin 13 
56.7 ± 
8.2 nM 
fluorescence binding 
assay 
37 
Single microbead 
SELEX 
Botulinum neurotoxin 2 3 nM 
fluorescence 
polarization  
39 
S
E
L
E
X
 w
it
h
o
u
t 
im
m
o
b
il
iz
a
ti
o
n
 
Free flow SELEX IgE 4 
29 ± 15 nM  
fluorescence 
polarization  
27 
58 ± 55  nM affinity capillary 
electrophoresis  
  
CE-SELEX 
  
IgE 2 40 nM 
affinity capillary 
electrophoresis 
26 
HIV1-RT 4 180 ± 70 pM 
affinity capillary 
electrophoresis 
29 
streptavidin 10 140 nM SPR 30 
Non-Selex h-Ras protein 3 300 nM 
non-equilibrium 
capillary 
electrophoresis of 
equilibrium mixtures  
31 
M
ic
ro
fl
u
id
ic
 s
el
ec
ti
o
n
 
  
M-SELEX 
  
Botulinum neurotoxin 
type A  
1 33 ± 8 nM 
fluorescence binding 
assay 
45 
Transcription factor 
IIB 
7 4 nM 
electrophoretic 
mobility shift assay  
19 
C-reactive protein 5 3.51 nM SPR 20 
Selection with 
micromagnetic 
separation chip 
Streptavidin 3 25-65 nM 
fluorescence binding 
assay 
46 
Platelet-Derived 
Growth Factor-BB 
3 0.028 nM 
fluorescence binding 
assay 
47 
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Figure Captions 639 
Figure 1. Elaborate 3D structures of aptamers.  Crystal and solution structure of von 640 
Willebrand factor [7] and the malachite green [8] binding aptamers A and B, respectively.  641 
Figure 2. Principle of the SELEX method to generate aptamers 642 
Figure 3. Comparative bubble graph of various techniques used for determining the 643 
dissociation constant of aptamer–protein complexes. The graph shows the smallest assessed KD 644 
values for aptamer–protein interaction with the respective techniques as a function of the 645 
minimal volume required for the analysis. 646 
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